S'abonner

Long bones giant cells tumors: Treatment by curretage and cavity filling cementation - 12/10/09

Doi : 10.1016/j.otsr.2009.07.004 
N. Fraquet a, G. Faizon b, P. Rosset b, J.-M. Phillipeau a, c, D. Waast a, F. Gouin a, , c
a Bone and Joint Unit, Hôtel Dieu teaching medical center, place A.-Ricordeau, 44093 Nantes cedex, France 
b Department of Orthopaedics, hôpital Trousseau, Tours teaching medical center, Tours, France 
c EA3822, Inserm U957, Bone resorption physiopathology and primary bone tumors therapy, research laboratory, Faculty of Medicine, Nantes University, Nantes, France 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Objective

Giant cell tumors (GCT) of bone are benign tumors with local aggressiveness that most of the time occur around the metaphyseal area of long bones, often in contact with the articular cartilage. Their treatment remains controversial because of their high recurrence rate. The authors report a retrospective series of 30 cases treated using curettage followed by cementation. They suggest demonstrating the mechanical and functional benefit of this technique, its benefit controlling the risk of recurrence, and of osteoarthritis potential.

Material and Methods

Between 1992 and 2005, 30 patients with GCT were treated using curettage and cementation. Twenty-six of these tumors were present around the knee: 14 at the distal femur and 12 at the proximal tibia. Preoperative radiological evaluation with standard X-rays showed that the tumor measured a mean 71×45mm, for a mean volume of 78cm3. Seventy-three percent of these GCT were in direct contact with the articular cartilage and 40% extended to the soft tissues as seen on the CAT scan and/or MRI. All patients were treated with curettage and cementation, 16 additional internal fixation procedures were performed. The mean follow-up of this series was 6 years and 4 months. All patients continue to be monitored, with none lost to follow-up.

Results

In all our cases, nine recurrences (30%) were observed during the first 2 years. Six patients were treated with a new curettage and cementation procedure and three underwent a total knee arthroplasty. None of these lesions had recurred at the last follow-up. The MSTS score, reflecting the function of the operated limb was a mean 93.33% (28±2/30). Standard radiological assessment showed a thin scalable border on four patients and was normal for the all-total arthroplasty cases. Two cases of minor osteoarthritis progression were noted (one less than 50% and a simple densification of subchondral bone), requiring no specific treatment. Three complications were noted: one leg deep venous thrombosis, one hematoma, and one deep infection without impacting the initial treatment outcome over the long term.

Discussion

The curettage and cementation technique is usual practice in GCT treatment. Simple and reproducible, this technique has a lower rate of complication than other treatment options such as cryotherapy. It produces a lower rate of recurrence with the dual benefit of excellent mechanical and functional qualities. Diagnosis of recurrence can be made earlier because of the thin scalable border at the bone-cement interface. This technique does not generally cause osteoarthritis, which was found in only two cases with no evidence of the cement having a direct effect. The 30% recurrence rate observed in this series shows that the benefit provided by the cement as an adjuvant preservative remains modest.

Conclusion

The cement mechanical and cytotoxic properties as well as its innocuity and its ease of handling make curettage and cementation one of the top-ranking GCT treatment options. An even lower rate of recurrence may be obtained through development of additional adjuvant treatments such as calcitonin and bisphosphonates.

Level of evidence

Level IV; Therapeutic study.

Le texte complet de cet article est disponible en PDF.

Keywords : Giant cell tumor, Cement, Curettage, PMMA


Plan


© 2009  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 95 - N° 6

P. 402-406 - octobre 2009 Retour au numéro
Article précédent Article précédent
  • Pelvic chondrosarcomas: Surgical treatment options
  • X. Deloin, V. Dumaine, D. Biau, M. Karoubi, A. Babinet, B. Tomeno, P. Anract
| Article suivant Article suivant
  • Prevention of dislocation in total hip revision surgery using a dual mobility design
  • R. Philippot, P. Adam, M. Reckhaus, F. Delangle, F.-X. Verdot, G. Curvale, F. Farizon

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.